The pathophysiology of secondary hyperparathyroidism and the consequences of uncontrolled mineral metabolism in chronic kidney disease: the role of COSMOS

Jorge B. Cannata-Andía¹ and Fernando Carrera²

¹University of Oviedo, Oviedo, Spain and ²Eurodial, Euromedic, Dialysis Unit, Leiria, Portugal

Abstract

The development of secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease. SHPT develops as a consequence of mineral metabolism disturbances and is characterized by elevated serum parathyroid hormone (PTH) and parathyroid hyperplasia. Evidence suggests that SHPT contributes to the development of vascular calcification and cardiovascular disease, as well as to the development of renal osteodystrophy. The elevated serum calcium, phosphorus, calcium–phosphorus product and PTH that accompany SHPT have been independently associated with an increased relative risk of mortality. Despite the danger that these risks represent, achieving control of mineral metabolism in SHPT is difficult. Recent evidence from the Current Management of Secondary Hyperparathyroidism: Multicentre Observational Study has shown that fewer than 1 in 10 haemodialysis patients simultaneously meet their National Kidney Foundation Kidney Disease Outcomes Quality Initiative targets for serum calcium, phosphorus, calcium–phosphorus product and PTH with standard treatments. There is therefore an urgent need for new strategies and novel pharmacologic therapies that improve control of mineral metabolism and PTH secretion in SHPT and thus reduce the mortality associated with this condition.

Keywords: calcium; haemodialysis; kidney; phosphorus; secondary hyperparathyroidism

Introduction

Phosphorus levels increase and active vitamin D (calcitriol) synthesis decreases in direct response to declining kidney function, triggering a cascade of sequelae including decreased calcium absorption and increased production of parathyroid hormone (PTH) [1–3]. Elevations in serum PTH concentration are observed early in the development of chronic kidney disease (CKD) [4]. As CKD progresses, serum PTH continues to rise [4] and patients typically develop secondary hyperparathyroidism (SHPT) [5]. Consequently, most of the patients receiving dialysis have persistently elevated serum PTH [6]. Prolonged hypocalcaemia, hyperphosphataemia and low vitamin D concentrations all contribute to the increased PTH synthesis and secretion and parathyroid gland hyperplasia that are the hallmarks of SHPT [7,8]. Prevention and treatment of SHPT are critical because these mineral metabolism imbalances are independently associated with increased morbidity and mortality in CKD patients [9] and add to the development of extrasosseous calcification, particularly in the vasculature [10,11], and bone disorders such as renal osteodystrophy [12]. This review discusses the pathophysiology of SHPT, the various clinical complications of uncontrolled mineral metabolism and the need for new strategies for SHPT treatment in CKD patients.

Pathophysiology of SHPT

Alterations in both phosphorus and calcium metabolism play critical roles in the development of SHPT. The kidney’s ability to remove phosphorus from circulating plasma is reduced in CKD, resulting in an accumulation of phosphorus in the serum [3]. One consequence of this increase in serum phosphorus is increased PTH synthesis and secretion, and parathyroid cell proliferation [1,13]. The kidney plays an equally important role in mineral metabolism through a second mechanism. The final step in the synthesis of 1,25-dihydroxyvitamin D₃ occurs in the kidney [14], and it is this active D₃ metabolite that is required for efficient absorption of calcium from the small intestine [15]. Calcium and 1,25-dihydroxyvitamin D₃ levels regulate a variety of processes, including bone morphogenesis and turnover in conjunction with PTH [15], calcium channel–mediated processes [16] and gene transcription at the subcellular level [17]. In CKD, the reduction in 1,25-dihydroxyvitamin D₃ and serum calcium triggers the release of PTH [18], which in turn promotes intestinal calcium absorption,
reabsorption of calcium in the kidney and the release of calcium from bone.

The calcium-sensing receptor (CaR), located on the surface of the chief cells of the parathyroid gland, plays a central role in the regulation of PTH secretion and synthesis, making it an important regulator of calcium homeostasis. In CKD, lowered serum calcium levels result in ongoing inactivation of the CaR, reduced signalling through the CaR and increased PTH synthesis and secretion [3,19]. As PTH secretion increases, calcium is released from bone tissue, enhancing phosphate excretion in the presence of a functioning kidney [20]. This response of the parathyroid gland depends on the rapidity and duration of the hypocalcaemic stress [21,22]. PTH release in response to calcium occurs within seconds to minutes following signalling through the CaR [22,23], chronic hypocalcaemic stress and hyperphosphataemia stimulate PTH gene expression and subsequent PTH synthesis within hours to days [24] and proliferation of parathyroid cells occurs over days to weeks [13].

The mechanisms governing the synthesis of PTH in the parathyroid gland are complex and still not fully understood. Although the nuclear vitamin D receptor (VDR) can suppress PTH gene transcription [18,25], PTH is also regulated post-transcriptionally by the binding of stabilizing RNA-binding post-proteins to the 3′ untranslated region of the PTH transcript [26,27]. Interestingly, the PTH transcript has a greater stability under conditions of low calcium and high phosphorus [19].

As CKD progresses towards stage 5, SHPT increases in severity, resulting in the proliferation of parathyroid cells and the development of diffuse hyperplasia [3]. This is accompanied by a decrease in CaR and VDR expression [28–30]. Because vitamin D is a potent inhibitor of PTH synthesis [18,31], a reduction in VDR expression might also inhibit the vitamin D–mediated signals that suppress PTH synthesis and release, although this has not yet been demonstrated experimentally. It is the hyperplastic nodules of the parathyroid gland that show the greatest change in both CaR and VDR expression [28,30], rendering them less responsive to circulating calcium. As parathyroid cells are transformed into a severe nodular hyperplastic state, a decline in VDR expression reduces the efficiency of vitamin D receptor activators in up-regulating the transcription of the CaR gene and in inhibiting parathyroid cell proliferation.

Clinical complications of uncontrolled mineral metabolism

Evidence suggests that the alterations in serum PTH and mineral metabolism in SHPT have important consequences for haemodialysis patients. Increased calcium and phosphorus concentrations are key contributors to SHPT-associated all-cause and cardiovascular (CV) mortality [9,32] and bone disease [12]. It is less recognized, but of equal importance, that PTH levels also significantly correlate with CV mortality risk. In a study of the correlation between the degree of deviation from National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQITM) targets (intact PTH [iPTH] 150–300 pg/mL) and the risk of CV death in patients undergoing dialysis (n = 59 567), Belozeroff et al. [33] demonstrated that increased PTH concentrations were significantly correlated with increased CV mortality risk (Figure 1). In another large study (n = 19 388) of CKD patients undergoing dialysis, Naves et al. [34] showed that the risk of CV death increased proportionally with increasing PTH concentrations, with a relative risk (RR) of 1.34 for 300–600 pg/mL and 1.52 for >600 pg/mL compared with the reference group of 150–300 pg/mL. Block et al. [9] reported a similar relationship between PTH levels and all-cause mortality in patients with stage 5 CKD.

Uncontrolled mineral metabolism also increases the risk of mortality. Naves et al. [34] documented that elevated mean serum concentrations of phosphorus (>5.0 mg/dL), calcium (>11 mg/dL) and calcium–phosphorus product (Ca × P; >50 mg²/dL²) were positively and significantly associated with increased RR of CV death. In contrast with data from other studies evaluated by Block et al. [35], serum calcium concentrations <8.5 mg/dL were also significantly associated with increased RR of CV death (RR = 1.87). In a study of a large cohort (n = 24 803) of haemodialysis patients, failure to achieve any KDOQITM targets for serum PTH (150–300 pg/mL), calcium (8.4–9.5 g/dL) and phosphorus (3.5–5.5 g/dL) was associated with an increased RR of death (RR = 1.51) compared with patients who achieved all three targets [36]. Achievement of either one or two KDOQITM targets was associated with proportional increases in the RR of death. Block et al. [37] have shown that the highest mortality rates are found in patients who have not achieved KDOQITM targets for Ca × P and PTH (Figure 2) [9,37].

Consistent with their contribution to CV mortality, increased serum phosphorus and Ca × P are associated with the development of vascular calcification [38,39]. Both calcium and phosphorus have been shown to directly promote mineralization in cultured smooth muscle cells [40,41]. Furthermore, phosphorus may contribute to
calcification by promoting increased PTH synthesis and secretion and parathyroid gland hyperplasia [42]. Arterial calcification results in stiffness and increased atherosclerotic load in the arteries [43], each of which increases the risk of a myocardial infarction and surgical complications. The risk of aortic calcification has been shown to be significantly higher in both men and women undergoing dialysis compared with age-matched patients in the general population (RR = 7.7 for men and RR = 9.0 for women) [44].

Another serious consequence of uncontrolled mineral metabolism is fracture [9,45]. In a cohort of patients from the European Vertebral Osteoporosis Study [44], the presence of vascular calcifications was positively and significantly associated with a higher risk of vertebral fractures (aortic calcification, RR = 1.9; femoral calcifications, RR = 3.2; uterus-spermatic calcifications, RR = 3.9) [44]. In addition, a significant increase (more than fivefold) in peripheral bone fractures was observed in patients undergoing dialysis compared with age-matched patients in the general population [44]. After 8 years of follow-up, mortality was directly correlated with severe vascular calcification in men (RR = 4.2) and bone fractures in women (RR = 2.2) [44].

**Challenges meeting recommended targets**

National Kidney Foundation KDOQITM guidelines were developed as recommendations based on a patient’s degree of kidney function [46]. For stage 5 CKD, the KDOQITM guidelines specify strict target concentrations of serum iPTH (150–300 pg/mL) and Ca × P (<55 mg²/dL²). Meeting the KDOQITM targets is, however, difficult and challenging. In fact, <10% of dialysis patients achieve combined targets for PTH, calcium, phosphorus and Ca × P [47–49]. In the international Dialysis Outcome Practice Patterns Study (DOPPS), Young et al. [50] investigated the associations between altered mineral metabolism and mortality in haemodialysis patients (n = 17 236). DOPPS, which was conducted before publication of the KDOQITM guidelines, demonstrated that the phosphorus and PTH levels in the majority of patients were outside the KDOQITM recommended ranges, and Ca × P exceeded the upper limit of the range in >40% of patients. In addition, all-cause and CV mortality were significantly associated with serum phosphorus, calcium and Ca × P concentrations.

To increase the knowledge of the impact of SHPT management strategies on outcomes, the Current Management of Secondary Hyperparathyroidism: Multicentre Observational Study (COSMOS) was initiated in February 2005 [49]. In this 3-year pan-European prospective observational cohort study, primary objectives include the association between clinical events and the achievement of KDOQITM and European best practice guidelines targets in patients undergoing haemodialysis [49,51]. The association between achievement of these targets and mortality, overall CV hospitalization, type of dialysis, type of centre and time on dialysis will be investigated. Secondary objectives include the association of targets with parathyroidectomy, manifest bone disease (including fractures), hospitalizations and vascular access, as well as the value of albumin and haemoglobin assessments in addition to bone mineral markers as predictors of mortality and clinical events.

This pan-European prospective study is currently enrolling with a target of 5700 haemodialysis patients from 20 countries in 285 centres into a web-based database [52]. Preliminary baseline data from 2759 patients indicate that <30% of patients had PTH concentrations within KDOQITM targets; 55% attained goal serum calcium, 50% attained goal serum phosphorus and 66% of patients were within Ca × P target limits [49]. Only 9% of patients simultaneously met all KDOQITM targets (Figure 3).
Pathophysiology and consequences of SHPT in CKD

Future directions in the management of SHPT

Once the COSMOS study is completed, these data will allow for a better understanding of the consequences of SHPT and the potential advantages of maintaining patients within therapeutic targets. Nevertheless, the available evidence from both COSMOS and DOPPS demonstrates the challenge of meeting KDOQITM targets with current standard care for SHPT in haemodialysis patients and emphasize the need for new strategies and the development of new treatments for the management of bone and mineral disorders. Recent advances in our understanding of the pathophysiology of SHPT in CKD have resulted in new therapeutic targets, in particular the CaR. Such new treatment options may improve the management of SHPT and outcomes in this patient population.

Acknowledgements. The authors wish to thank Dylan Harris and Ali Hassan for providing medical writing assistance in the preparation of this manuscript, and Cristina Risgo for invaluable editorial assistance. This supplement and online open access are sponsored by Amgen Inc.

Conflict of interest statement. Jorge B. Cannata-Andia has been a member of international steering committees and scientific advisory boards of Amgen, Abbott, Shire and Roche. Fernando Carrera is a scientific consultant, a member of steering committees for international clinical trials and/or a member of international advisory boards for the following companies: Amgen (Europe), Roche (International) and Shire (International).

References
1. Almaden Y, Hernandez A, Torregrosa V et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998; 9: 1845–1852
2. Slatopolsky E, Finch J, Denda M et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534–2540
3. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol 2005; 288: F253–F264
4. Martinet I, Saracho R, Montenego J, Llach F. The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997; 29: 496–502
5. Owda A, Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail 2003; 25: 595–602
6. Salem MM. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis 1997; 29: 862–865
7. de Francisco AL. Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs. Expert Opin Pharmacother 2006; 7: 2215–2224
8. Rodriguez M, Canalejo A, Garfia B, Aguilera E, Almaden Y. Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int Suppl 2002; 155–160
9. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208–2218
10. Braun J, Oldendorf M, Moshage W, Heidler R, Reitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394–401
11. Tokuyama T, Ikeda T, Sato K, Mimura O, Morita A, Tabata T. Conjunctival and corneal calcification and bone metabolism in hemodialysis patients. Am J Kidney Dis 2002; 39: 291–296
12. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002; 17: 2094–2105
13. Naveh-Many T, Rahaminov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995; 96: 1786–1793
14. Kumar R. The metabolism and mechanism of action of 1,25-dihydroxyvitamin D3. Kidney Int 1986; 30: 793–803
15. Parodi DA, Miao D, Bolivar I et al. Inactivation of the 25-hydroxyvitamin D alphahydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004; 279: 16754–16766
16. Hoenderop JG, Muller D, Van Der Kemp AW et al. Calcitriol controls the epithelial calcium channel in kidney. J Am Soc Nephrol 2001; 12: 1342–1349
17. Demay MB, Kierman MS, DeLuca HF, Kronenberg HM. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1992; 89: 8097–8101
18. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986; 78: 1296–1301
19. Moalem E, Kilav R, Silver J, Naveh-Many T. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 1998; 273: 5253–5259
20. Bricker NS. On the pathogenesis of the uremic state. An exposition of the “trade-off hypothesis”. N Engl J Med 1972; 286: 1093–1099
21. Brent GA, LeBoff MS, Seely EW, Conlin PR, Brown EM. Relationship between the concentration and rate of change of calcium and serum intact parathyroid hormone levels in normal humans. J Clin Endocrinol Metab 1988; 67: 944–950
22. Brown EM. Calcium receptor and regulation of parathyroid hormone secretion. Rev Endocr Metab Disord 2000; 1: 307–315
23. Hanley DA, Takatsuki K, Sultan JM, Schneider AB, Sherwood LM. Direct release of parathyroid hormone fragments from functioning bovine parathyroid glands in vitro. J Clin Invest 1978; 62: 1247–1254
24. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990; 86: 1313–1319
25. Silver J, Moalem E, Kilav R, Sela A, Naveh-Many T. Regulation of the parathyroid hormone gene by calcium, phosphate and 1,25-dihydroxyvitamin D. Nephrol Dial Transplant 1998; 13(Suppl 1): A40–A44
26. Kilav R, Silver J, Naveh-Many T. A conserved cis-acting element in the parathyroid hormone 3′-untranslated region is sufficient for regulation of RNA stability by calcium and phosphate. J Biol Chem 2001; 276: 8727–8733
27. Sela-Brown A, Silver J, Brewer G, Naveh-Many T. Identification of AU1F1 as a parathyroid hormone mRNA 3′-untranslated region-binding protein that determines parathyroid hormone mRNA stability. J Biol Chem 2000; 275: 7424–7429
28. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436–1443
29. Kifor O, Moore FD Jr, Wang P et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 1598–1606
30. Gogus P, Duchambon P, Hulbert-Shearon T, Port FK. Association of elevated serum PO4,Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131–2138
33. Belozeroff V, Klassen P, Wentworth C, Ofsthun N, Arab L, Rothman KJ. Effects of uncontrolled biochemical parameters on cardiovascular mortality in dialysis patients [Abstract SP253]. Nephrol Dial Transplant 2005; 20(Suppl 5): v103–v104

34. Naves M, Guinsburg A, Marelli C et al. Relative risk of death according to serum Ca, P, and PTH. Results from a large sample of dialysis patients from Latin America followed for up to 54 months. Presented at: Renal Week, 8–13 November 2005; Philadelphia, PA, USA

35. Block GA, Hulbert-Shearon T, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–617

36. Belozeroff V, Danese M, Smirnakis K, Rothman KJ. Association of parathyroid hormone (PTH), phosphorus (P), and calcium (Ca) KDOQITM target achievement with mortality in patients on dialysis. Presented at: Renal Week, 8–13 November 2006; Philadelphia, PA, USA

37. Block GA, Klassen P, Danese M. Association between proposed NKF-K/DOQI bone metabolism and disease guidelines and mortality risk in hemodialysis patients. J Am Soc Nephrol 2003; 14: 474A

38. Ishimura E, Taniwaki H, Tabata T et al. Cross-sectional association of serum phosphate with carotid intima-medial thickness in hemodialysis patients. Am J Kidney Dis 2005; 45: 859–865

39. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478–1483

40. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293–2299

41. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10–E17

42. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226–1237

43. Shanahan CM, Proudfoot D, Farzaneh-Far A, Weissberg PL. The role of Gla proteins in vascular calcification. Crit Rev Eukaryot Gene Expr 1998; 8: 357–375

44. Rodriguez-Garcia M, Naves M, Cannata-Andia J. Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence. J Nephrol 2005; 18: 458–463

45. Kim J, Dylan M, Doan Q et al. Association of elevated serum parathyroid hormone (PTH) and calcium with hip, vertebral, or pelvic fracture in hemodialysis patients [Abstract S026]. Presented at: ERA-EDTA Congress, 15–18 May 2004; Lisbon, Portugal

46. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1–S201

47. Cannata-Andia J, Fernández-Martin JL, Diaz-Corte C, for the ROD Multicenter Study. Applying the K/DOQI guidelines cut-off values to the dialysis population: How far are we from the target? J Am Soc Nephrol 2003; 14: 474A

48. Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 34–38

49. Fernández-Martin J, Ferreira A, Floege J et al. Results from the initial cross-sectional analysis of the COSMOS baseline population. Presented at: ERA-EDTA, 16–18 July, 2006; Glasgow, UK

50. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179–1187

51. Fernández-Martín J, Gorriz J, Ketteler M et al. Guidelines and bone mineral management in facilities in the pan-European COSMOS study. Presented at: ERA-EDTA, 16–18 July 2006; Glasgow, UK

52. Fernández-Martín J, Gorriz J, Ketteler M et al. Achievement of K/DOQI targets in European hemodialysis (HD) patients (Pts) in the COSMOS Study: differences between prevalent and incident Pts. Presented at: Renal Week, 8–13 November, 2006; Philadelphia, PA, USA

Received for publication: 17.7.07
Accepted in revised form: 10.9.07